{"disease":{"id":"hyperlipoproteinemia","name":"Hyperlipoproteinemia","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":2,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"atorvastatin","indication_name":"Familial type 3 hyperlipoproteinemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lipitor","generic_name":"atorvastatin","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"HMG-CoA reductase","drug_class":"HMG-CoA reductase inhibitor (statin)","quality_score":77,"revenue":"1000.0","mechanism":"Selective competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis."},{"drug_id":"simvastatin","indication_name":"Familial type 3 hyperlipoproteinemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zocor","generic_name":"simvastatin","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Nuclear receptor subfamily 1 group I member 3, Nuclear receptor subfamily 4 group A member 2, 3-hydroxy-3-methylglutaryl-coenzyme A reductase","drug_class":"HMG-CoA Reductase Inhibitor [EPC]","quality_score":40,"revenue":null,"mechanism":null},{"drug_id":"acipimox","indication_name":"Hyperlipoproteinemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Olbemox","generic_name":"ACIPIMOX","company_name":"","drug_phase":"phase_3","molecular_target":"Hydroxycarboxylic acid receptor 2","drug_class":"acipimox","quality_score":null,"revenue":null,"mechanism":"Olbemox works by activating the hydroxycarboxylic acid receptor 2, which helps to reduce the production of triglycerides in the liver."},{"drug_id":"rosuvastatin","indication_name":"Familial type 3 hyperlipoproteinemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Crestor","generic_name":"rosuvastatin","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"HMG-CoA reductase","drug_class":"HMG-CoA reductase inhibitor (statin)","quality_score":74,"revenue":null,"mechanism":"Rosuvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme converting HMG-CoA to mevalonate, a cholesterol precursor."},{"drug_id":"lipitor","indication_name":"Familial type 3 hyperlipoproteinemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lipitor","generic_name":"Atorvastatin Calcium","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"3-hydroxy-3-methylglutaryl-coenzyme A reductase","drug_class":"atorvastatin","quality_score":10,"revenue":null,"mechanism":"Lipitor is a selective, competitive inhibitor of HMG-CoA reductase, a key enzyme in cholesterol synthesis."},{"drug_id":"olbetam","indication_name":"Hyperlipoproteinemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Olbetam","company_name":"University of Aarhus","drug_phase":"phase_1","molecular_target":"Hydroxycarboxylic acid receptor 2","drug_class":"","quality_score":4,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":6,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06304415","title":"Elevated Lipoprotein(a) in Hospital Staff","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2800,"lead_sponsor_name":"Changi General Hospital","has_results":false},{"nct_id":"NCT00552097","title":"Effect of Ezetimibe Plus Simvastatin Versus Simvastatin Alone on Atherosclerosis in the Carotid Artery (ENHANCE)(P02578)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":720,"lead_sponsor_name":"Organon and Co","has_results":false},{"nct_id":"NCT05425745","title":"Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":354,"lead_sponsor_name":"NewAmsterdam Pharma","has_results":true},{"nct_id":"NCT01524289","title":"Study to Assess the Tolerability and Efficacy of Anacetrapib (MK-0859) Co-Administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":306,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT04516291","title":"A Dose-Ranging Study With Vupanorsen (TRANSLATE-TIMI 70)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":286,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT06439654","title":"Atlantic Lipid Lowering Treatment Optimization Program","phase":"NA","overall_status":"RECRUITING","enrollment_count":250,"lead_sponsor_name":"Atlantic Health System","has_results":false},{"nct_id":"NCT05256654","title":"A Study of LY3561774 in Participants With Mixed Dyslipidemia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":205,"lead_sponsor_name":"Eli Lilly and Company","has_results":true},{"nct_id":"NCT06526013","title":"Cholesterol Self-testing in Patients Post Acute Coronary Syndrome","phase":"NA","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"University of Leipzig","has_results":false},{"nct_id":"NCT04330209","title":"Comparing a Low-GI Nutrigenetic and Ketogenic Diet for Weight Loss With 18 Month Follow-up","phase":"","overall_status":"COMPLETED","enrollment_count":114,"lead_sponsor_name":"Iuliu Hatieganu University of Medicine and Pharmacy","has_results":false},{"nct_id":"NCT05661552","title":"Effect of Early Initiation of Evolocumab on Lipid Profiles Changes in Patients With ACS Undergoing PCI","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":108,"lead_sponsor_name":"Yonsei University","has_results":false},{"nct_id":"NCT07405814","title":"Clinical Trial On The Effect Of Artisterol On Risk Factors In Individuals With Suboptimal Cholesterol Levels","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":106,"lead_sponsor_name":"Zentiva, k.s.","has_results":false},{"nct_id":"NCT06154408","title":"Evaluating the Impact of Omega-3 Fatty Acid Supplementation (Soloways™) on Lipid Profiles in Adults With PPARG Polymorphisms","phase":"NA","overall_status":"COMPLETED","enrollment_count":102,"lead_sponsor_name":"S.LAB (SOLOWAYS)","has_results":false},{"nct_id":"NCT02658175","title":"The Approach Open Label Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Chylomicronemia Syndrome","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":68,"lead_sponsor_name":"Akcea Therapeutics","has_results":true},{"nct_id":"NCT04261803","title":"FH Detection in Children by Salivary Test","phase":"","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT06163443","title":"Evaluating the Impact of B Vitamin Supplementation (Soloways™) on Homocysteine and LDL-C Levels in Patients With MTHFR, MTR, and MTRR Polymorphisms.","phase":"NA","overall_status":"COMPLETED","enrollment_count":54,"lead_sponsor_name":"S.LAB (SOLOWAYS)","has_results":false},{"nct_id":"NCT05305664","title":"A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Rate of Weekly Lipoprotein Apheresis Sessions in Patients With Hyperlipoproteinemia(a) and Established Cardiovascular Disease in Germany","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":51,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06420817","title":"Effect of a Customised Lifestyle Medicine Strategy on Lowering Blood Lipid Levels in Indian Physicians","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":50,"lead_sponsor_name":"Jubilee Mission Medical College and Research Institute","has_results":false},{"nct_id":"NCT05900141","title":"An Open Label Extension (OLE) Study to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":41,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT03607383","title":"Red Rice Yeast in Low-density Lipoprotein (LDL) Lowering: an Efficacy Study","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Saint-Joseph University","has_results":false},{"nct_id":"NCT07157878","title":"Gingival Crevicular Fluid Oxidized Low-Density Lipoprotein Levels in Health and Stage III/IV Periodontitis","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":40,"lead_sponsor_name":"shaimaa hamdy","has_results":false},{"nct_id":"NCT06333158","title":"Extracts of Amla, Walnut Leaf, Red Yeast Rice and Olive in Cardiovascular Prevention","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"Nina Hermans","has_results":false},{"nct_id":"NCT03360747","title":"Phase 2 Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Chylomicronemia Syndrome (FCS)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":3,"lead_sponsor_name":"Akcea Therapeutics","has_results":true}],"total":22},"guidelines":[],"source":"Drug Landscape verified database"}